Anonymous User
Login / Registration

Gastroenterologie
a hepatologie

Gastroenterology and Hepatology

. doi:10.48095/ccgh2020499.

Joint opinion of professional societies on pharmacological treatment of obesity

Martin Fried1, Dana Müllerová2, Martin Haluzík3, Petr Sucharda4, Jan Boženský5, Vojtěch Hainer6, Marie Kunešová6, Iva Málková7, Šárka Slabá8, Radka Taxová-Braunerová6, Petra Šrámková1, Pavol Holeczy5

+ Affiliation

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users

Literature

1. König HH, Lehnert T, Brenner H et al. Health service use and costs associated with excess weight in older adults in Germany. Age Ageing 2015; 44 (4): 616–623. doi: 10.1093/ageing/afu120.

2. Specchia ML, Veneziano MA, Cadeddu C et al. Economic impact of adult obesity on health systems: a systematic review. Eur J Public Health 2015; 25 (2): 255–262. doi: 10.1093/eurpub/cku170.

3. Tremmel M, Gerdtham UG, Nilsson PM et al. Economic burden of obesity: a systematic literature review. Int J Environ Res Public Health 2017; 14 (4): 435. doi: 10.3390/ijerph14040435.

4. Flegal KM, Panagiotou OA, Graubard BI. Estimating population attributable fractions to quantify the health burden of obesity. Ann Epidemiol 2015; 25 (3): 201–207. doi: 10.1016/j.annepidem.2014.11.010.

5. Hebebrand J, Holm JC, Woodward E et al. A proposal of the European association for the study of obesity to improve the ICD-11 dia gnostic criteria for obesity based on the three dimensions etiology, degree of adiposity and health risk. Obes Facts 2017; 10 (4): 284–307. doi: 10.1159/000479208.

6. Yumuk V, Tsigos C, Fried M et al. European guidelines for obesity management in adults. Obes Facts 2015; 8 (6): 402–424. doi: 10.1159/000442721.

7. Greenway FL. Physiological adaptations to weight loss and factors favouring weight regain. Int J Obes (Lond) 2015; 39 (8): 1188–1196. doi: 10.1038/ijo.2015.59.

8. Sumithran P, Prendergast LA, Delbridge E et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med 2011; 365 (17): 1597–1604. doi: 10.1056/NEJMoa1105816.

9. Jensen MD, Ryan DH, Apovian CM et al. 2013 AHA/ACC/TOS guideline for the mana gement of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 2014; 63 (25 Pt B): 2985–3023. doi: 10.1016/j.jacc.2013.11.004.

10. Lean ME, Leslie WS, Barnes AC et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 2018; 391 (10120): 541–551. doi: 10.1016/S0140-6736 (17) 33102-1.

11. Schutz DD, Busetto L, Dicker D et al. European practical and patient-centred guidelines for adult obesity management in primary care. Obes Facts 2019; 12 (1): 40–66. doi: 10.1159/000496183.

12. Wadden TA, West DS, Neiberg RH et al. One-year weight losses in the Look AHEAD study: factors associated with success. Obesity (Silver Spring) 2009; 17 (4): 713–722. doi: 10.1038/oby.2008.637.

13. Hainer V. Základy klinické obezitologie. Praha: Grada 2011.

14. Sjöström L, Rissanen A, Andersen T et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998; 352 (9123): 167–172. doi: 10.1016/s0140-6736 (97) 11509-4.

15. Leblanc ES, O’Connor E, Whitlock EP et al. Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155 (7): 434–447. doi: 10.7326/0003-4819-155-7-201110040-00006.

16. Torgerson JS, Hauptman J, Boldrin MN et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27 (1): 155–161. doi: 10.2337/diacare.27.1.155.

17. Davidson MH, Hauptman J, DiGirolamo M et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281 (3): 235–242. doi: 10.1001/jama.281.3.235.

18. Kelley DE, Bray GA, Pi-Sunyer FX et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care 2002; 25 (6): 1033–1041. doi: 10.2337/diacare.25.6.1033.

19. Tonstad S, Pometta D, Erkelens DW et al. The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol 1994; 46 (5): 405–410. doi: 10.1007/BF00191901.

20. Hvizdos KM, Markham A. Orlistat: a review of its use in the management of obesity. Drugs 1999; 58 (4): 743–760. doi: 10.2165/00003495-19995804 0-00015.

21. McNeely W, Benfield P. Orlistat. Drugs 1998; 56 (2): 241–250. doi: 10.2165/00003495-19985 6020-00007.

22. Greig SL, Keating GM. Naltrexone ER/Bupropion ER: a review in obesity management. Drugs 2015; 75 (11): 1269–1280. doi: 10.1007/ s40265-015-0427-5.

23. Caixàs A, Albert L, Capel I et al. Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date. Drug Des Devel Ther 2014; 8: 1419–1427. doi: 10.2147/DDDT.S55587.

24. Greenway FL, Dunayevich E, Tollefson G et al. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab 2009; 94 (12): 4898–4906. doi: 10.1210/jc.2009-1350.

25. Hollander P, Gupta AK, Plodkowski R et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 2013; 36 (12): 4022–4029. doi: 10.2337/dc13-0234.

26. Wadden TA, Foreyt JP, Foster GD et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 2011; 19 (1): 110–120. doi: 10.1038/oby.2010.147.

27. Nissen SE, Wolski KE, Prcela L et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA 2016; 315 (10): 990–1004. doi: 10.1001/jama.2016.1558.

28. Bode B. An overview of the pharmacokinetics, efficacy and safety of liraglutide. Diabetes Res Clin Pract 2012; 97 (1): 27–42. doi: 10.1016/j.diabres.2011.12.015.

29. Jacobsen LV, Flint A, Olsen AK et al. Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2016; 55 (6): 657–672. doi: 10.1007/s40262-015-0343-6.

30. van Can J, Sloth B, Jensen CB et al. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond) 2014; 38 (6): 784–793. doi: 10.1038/ijo.2013.162.

31. Flint A, Kapitza C, Hindsberger C et al. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. Adv Ther 2011; 28 (3): 213–226. doi: 10.1007/s12325-010-0110-x.

32. Horowitz M, Flint A, Jones KL et al. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract 2012; 97 (2): 258–266. doi: 10.1016/j.diabres.2012.02.016.

33. Pi-Sunyer X, Astrup A, Fujioka K et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015; 373 (1): 11–22. doi: 10.1056/NEJMoa1411 892.

34. le Roux CW, Astrup A, Fujioka K et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 2017; 389 (10077): 1399–1409. doi: 10.1016/S0140-6736 (17) 30069-7.

35. Davies MJ, D‘Alessio DA, Fradkin J et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Dia Care 2018; 41 (12): 2669–2701. doi: 10.2337/dci18-0033.

36. Wadden TA, Hollander P, Klein S et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study. Int J Obes (Lond) 2015; 39 (1): 187. doi: 10.1038/ijo.2014.88.

37. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep 1999; 22 (5): 667–689.

38. Marso SP, Daniels GH, Brown-Frandsen K et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375 (4): 311–322. doi: 10.1056/NEJMoa1603827.

39. Bays H, Pi-Sunyer X, Hemmingsson JU et al. Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects. Curr Med Res Opin 2017; 33 (2): 225–229. doi: 10.1080/03007995.2016.1251892.

40. Kolotkin RL, Fujioka K, Wolden ML et al. Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clin Obes 2016; 6 (4): 233–242. doi: 10.1111/cob.12146.

41. Blackman A, Foster GD, Zammit G et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial. Int J Obes (Lond) 2016; 40 (8): 1310–1319. doi: 10.1038/ijo.2016.52.

42. Fujioka K, O‘neil PM, Davies M et al. Early weight loss with liraglutide 3.0 mg predicts 1-year weight loss and is associated with improvements in cinical markers. Obesity (Silver Spring) 2016; 24 (11): 2278–2288. doi: 10.1002/oby.21629.

43. Wadden TA, Walsh OA, Berkowitz RI et al. Intensive behavioral therapy for obesity combined with liraglutide 3.0 mg: a randomized controlled trial. Obesity (Silver Spring) 2019; 27 (1): 75–86. doi: 10.1002/oby.22359.

44. Modi R, Rye P, Cawsey et al. Liraglutide effects on upper gastrointestinal investigations: implications prior to bariatric surgery. Obes Surg2018; 28 (7): 2113–2116. doi: 10.1007/s11695-018-3249-1.

45. Suliman M, Buckley A, Tikriti AA et al. Routine clinical use of liraglutide 3 mg for the treatment of obesity: outcomes in non‐surgical and bariatric surgery patients. Diabetes Obes Metab 2019; 21 (6): 1498–1501. doi: 10.1111/dom.13672.

Kreditovaný autodidaktický test